Salarius Pharmaceuticals focuses on developing drug candidates that it is co-advancing with Decoy Therapeutics, although the specific therapeutic areas have not been publicly detailed. The company’s most recent communications emphasize moving multiple clinical programs forward while also retiring Decoy’s outstanding obligations ahead of an expected business combination between the two firms. Management has chosen a capital-efficient approach that leans heavily on private placements and investor warrants, accepting the attendant dilution risk in exchange for near-term cash. Proceeds from its latest round are earmarked for clinical development and debt reduction. Observers note that the firm lacks the platform clarity that many venture-backed peers showcase, which could challenge future fundraising. Market reaction to its latest raise was mixed, with shares trading lower after the announcement, highlighting investor concerns about valuation and dilution. Salarius’s future hinges on transparent execution and demonstrating a defensible therapeutic edge to secure follow-on capital.

Total raised

$7M

Funding rounds

2

Latest round

Equity

Latest activity

Nov 2025